News archive

May 2015

• • 20 May 2015
  • KBI Biopharma

  Merus and Selexis Receive a €2.1 Million Grant for Single-Cell-Line Manufacturing of a Bispecific Antibody Combinatio...

  With the best-in-class RCB generation capabilities of Selexis on board, the existing knowledge and infrastructure for the manufacturing of therapeutic monoclonal antibodies is optimally leveraged.

March 2015

• • 3 March 2015
  • Crown Bioscience

  Crown Bioscience Launches Life Science Product Catalog

  TOOLS TO SUPPORT PRECLINICAL RESEARCH, DRUG DEVELOPMENT AND VALIDATION

February 2015

• • 26 February 2015
  • KBI Biopharma

  JSR Corporation and KBI Biopharma, Inc. Agree to Acquisition; INCJ and CMIC of Japan also participate

  JSR continues to demonstrate its commitment to the life sciences industry, by expanding its bioprocess capabilities and gaining a strong, successful partner.

• • 12 February 2015
  • Crown Bioscience

  Crown Bioscience Acquires Molecular Response’s Patient Derived Xenograft (PDX) Business

  Crown is acquiring all of Molecular Response’s existing PDX models as well as 8,000 viable human tumors for model development from Molecular Response’s viable tumor bank of over 140,000 unique cryo...

January 2015

• • 22 January 2015
  • KBI Biopharma

  Selexis-Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing

  Selexis SA is the First biotechnology Company to Deliver Manufacturing-Ready Research Cell Banks with a Fully Sequenced Genome and Transcriptome

• • 15 January 2015
  • Crown Bioscience

  Crown Bioscience Announces First European Symposium on Translational Oncology and the use of Patient-Derived Xenograf...

  KEY OPINION LEADERS TO DISCUSS THE USE OF TRANSLATIONAL PLATFORMS IN ACCELERATING ONCOLOGY DRUG DISCOVERY

• • 8 January 2015
  • KBI Biopharma

  First Selexis SUREtechnology-Generated Therapeutic Monoclonal Antibody Approved for Market

  The Selexis SURE CHO-M Cell Line™ is a proprietary high-performance mammalian cell line derived from CHO-K1 cells.